People

David Friedman, MD

David Friedman, MD is managing director and senior analyst for the healthcare and biotechnology Averill strategy at Montanova Capital, formerly Suvretta Capital Management. He joined the manager in January2020 according to issuer filings. His previous experience includes healthcare analysis at Scopia Capital and biotechnology equity research at Morgan Stanley. He holds an MBA from Harvard Business School, an MD from the University of Pittsburgh School of Medicine and a biology degree from Duke University. His source-published board experience includes Click Therapeutics, Veradermics, Avalyn and Sapphiros; a company board role is not a personal cash ticket.